| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 13/05/2024 | 13:06 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:BOLD | Boundless Bio Inc |
| 13/05/2024 | 13:05 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:BOLD | Boundless Bio Inc |
| 13/05/2024 | 13:00 | Business Wire | Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights | NASDAQ:BOLD | Boundless Bio Inc |
| 06/05/2024 | 14:00 | Business Wire | Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024 | NASDAQ:BOLD | Boundless Bio Inc |
| 11/04/2024 | 14:00 | Business Wire | Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications | NASDAQ:BOLD | Boundless Bio Inc |
| 08/04/2024 | 14:00 | Business Wire | Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024 | NASDAQ:BOLD | Boundless Bio Inc |
| 14/02/2020 | 23:23 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:BOLD | Boundless Bio Inc |
| 11/02/2020 | 22:41 | Edgar (US Regulatory) | Statement of Ownership (sc 13g) | NASDAQ:BOLD | Boundless Bio Inc |
| 27/01/2020 | 15:38 | Edgar (US Regulatory) | Termination of Registration of a Class of Security Under Section 12(b) (15-12b) | NASDAQ:BOLD | Boundless Bio Inc |
| 21/01/2020 | 12:00 | Edgar (US Regulatory) | Notice of Effectiveness (effect) | NASDAQ:BOLD | Boundless Bio Inc |
| 04/12/2019 | 01:13 | PR Newswire (US) | SHAREHOLDER ALERT: WeissLaw LLP Investigates Audentes Therapeutics, Inc. | NASDAQ:BOLD | Boundless Bio Inc |
| 03/12/2019 | 00:01 | Business Wire | Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics | NASDAQ:BOLD | Boundless Bio Inc |
| 26/11/2019 | 22:01 | Business Wire | Audentes Therapeutics to Participate in Upcoming Investor Conferences | NASDAQ:BOLD | Boundless Bio Inc |
| 12/11/2019 | 23:33 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:BOLD | Boundless Bio Inc |
| 07/11/2019 | 23:18 | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:BOLD | Boundless Bio Inc |
| 07/11/2019 | 22:08 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:BOLD | Boundless Bio Inc |
| 07/11/2019 | 22:01 | Business Wire | Audentes Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update | NASDAQ:BOLD | Boundless Bio Inc |
| 31/10/2019 | 12:00 | Business Wire | Audentes Therapeutics to Release Third Quarter 2019 Financial Results and Provide Corporate Update on Thursday, November 7, 2... | NASDAQ:BOLD | Boundless Bio Inc |
| 05/10/2019 | 13:01 | Business Wire | Audentes Therapeutics Presents New Positive Data from ASPIRO, the Clinical Trial Evaluating AT132 in Patients with X-Linked M... | NASDAQ:BOLD | Boundless Bio Inc |
| 05/10/2019 | 00:00 | Business Wire | Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:BOLD | Boundless Bio Inc |
| 30/09/2019 | 14:00 | Business Wire | Audentes Announces Upcoming Presentations at the 24th International Annual Congress of the World Muscle Society, Including Ne... | NASDAQ:BOLD | Boundless Bio Inc |
| 23/08/2019 | 22:03 | Edgar (US Regulatory) | Amended Current Report Filing (8-k/a) | NASDAQ:BOLD | Boundless Bio Inc |
| 06/08/2019 | 22:01 | PR Newswire (US) | Audentes Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update | NASDAQ:BOLD | Boundless Bio Inc |
| 30/07/2019 | 14:00 | PR Newswire (US) | Audentes Therapeutics to Release Second Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, August 6, 201... | NASDAQ:BOLD | Boundless Bio Inc |
| 17/07/2019 | 22:25 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) | NASDAQ:BOLD | Boundless Bio Inc |
| 29/05/2019 | 22:01 | PR Newswire (US) | Audentes Therapeutics Announces Changes to Senior Management Team | NASDAQ:BOLD | Boundless Bio Inc |
| 13/05/2019 | 12:04 | Edgar (US Regulatory) | Securities Registration: Employee Benefit Plan (s-8) | NASDAQ:BOLD | Boundless Bio Inc |
| 08/05/2019 | 14:00 | PR Newswire (US) | Audentes Therapeutics to Participate in the Bank of America Merrill Lynch 2019 Health Care Conference | NASDAQ:BOLD | Boundless Bio Inc |
| 07/05/2019 | 22:01 | PR Newswire (US) | Audentes Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update | NASDAQ:BOLD | Boundless Bio Inc |
| 01/05/2019 | 20:15 | PR Newswire (US) | Audentes Therapeutics Presents New Positive Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 for X-linked Myotubular M... | NASDAQ:BOLD | Boundless Bio Inc |